PDS Biotechnology Corp
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540
Mailing Address 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540
Phone 800-208-3343
Fiscal Year End 1231
EIN 264231384
Financial Overview
FY2025
-$8.33M
Net Income
$45.36M
Total Assets
$41.69M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
Annual Reports
10-K March 30, 2026
- PDS0101 entered a critical Phase 3 trial for head and neck cancer.
- Positive Phase 2 results demonstrated superior performance over standard care.
Material Events
8-K Financial Distress March 3, 2026
High Impact
- Positive Phase 2 clinical trial results for PDS0101 in HPV16-positive head and neck cancer.
- PDS0101 showed significant promise with improved overall response rate (ORR), complete response rate (CR), progression-free survival (PFS), and overall survival (OS).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.